AR123760A1 - METHODS TO TREAT CANCER - Google Patents
METHODS TO TREAT CANCERInfo
- Publication number
- AR123760A1 AR123760A1 ARP210102808A ARP210102808A AR123760A1 AR 123760 A1 AR123760 A1 AR 123760A1 AR P210102808 A ARP210102808 A AR P210102808A AR P210102808 A ARP210102808 A AR P210102808A AR 123760 A1 AR123760 A1 AR 123760A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- her2
- egfr
- disorder
- disease
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación proporciona entidades químicas (p. ej., un compuesto o una sal farmacéuticamente aceptable, y/o un hidrato, y/o un cocristal, y/o una combinación de fármacos del compuesto) que inhiben el receptor del factor de crecimiento epidérmico (EGFR, ERBB1) y/o el receptor del factor de crecimiento epidérmico humano 2 (HER2, ERBB2). Estas entidades químicas son útiles, p. ej., para tratar una afección, enfermedad o trastorno en que el aumento (p. ej., excesivo) de la activación del EGFR y/o del HER2 contribuye a la patología y/o a los síntomas y/o a la progresión de la afección, enfermedad o trastorno (p. ej., cáncer) en un sujeto (p. ej., un humano). La presente divulgación también proporciona composiciones que las contienen, así como métodos de uso y fabricación de estas.The present disclosure provides chemical entities (eg, a compound or a pharmaceutically acceptable salt, and/or a hydrate, and/or a co-crystal, and/or a drug combination of the compound) that inhibit growth factor receptor epidermal (EGFR, ERBB1) and/or human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g. to treat a condition, disease, or disorder in which increased (eg, excessive) activation of EGFR and/or HER2 contributes to the pathology and/or symptoms and/or progression of the condition , disease or disorder (eg, cancer) in a subject (eg, a human). The present disclosure also provides compositions containing them, as well as methods of using and manufacturing them.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089965P | 2020-10-09 | 2020-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123760A1 true AR123760A1 (en) | 2023-01-11 |
Family
ID=85131307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102808A AR123760A1 (en) | 2020-10-09 | 2021-10-12 | METHODS TO TREAT CANCER |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR123760A1 (en) |
-
2021
- 2021-10-12 AR ARP210102808A patent/AR123760A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123305T1 (en) | SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 REGULATORS | |
| CL2023000856A1 (en) | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer | |
| DOP2019000020A (en) | TIAZOLO-PYRIDINE COMPOUNDS REPLACED AS INHIBITORS OF MALT1 | |
| UY38196A (en) | CYCLINE-DEPENDENT KINASE INHIBITORS | |
| NI201500123A (en) | QUINAZOLINE INHIBITORS OF MUTATED FORMS ACTIVATING THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR | |
| CL2020000427A1 (en) | 3- (1-oxoisoindolin-2-yl) piperidine-2,6-dione derivatives and uses thereof. | |
| UY38751A (en) | COMPOUNDS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH STING ACTIVITY | |
| MX2018012249A (en) | Nlrp3 modulators. | |
| CU20190051A7 (en) | COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS THAT HAVE MUTATIONS IN EXON 20 OF EGFR OR HER2 | |
| UY39005A (en) | COMPOUNDS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH STING ACTIVITY | |
| UY39006A (en) | COMPOUNDS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH STING ACTIVITY | |
| SV2006002143A (en) | USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM | |
| NI201000145A (en) | DERIVATIVES OF IMIDAZINE - [1, 2-b] - PYRIDAZINE FOR THE TREATMENT OF DISEASE MEDIATED BY TYROSINE KINASE C-MET. | |
| BR112023006531A2 (en) | HETEROCYLIC EGFR AND/OR HER2 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | |
| UY38905A (en) | COMPOUNDS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH STING ACTIVITY | |
| ECSP066457A (en) | 5-ARILPIRIMIDINAS AS ANTI-CANCER AGENTS | |
| UY39328A (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE STING | |
| CL2016000816A1 (en) | Dosage form comprising the compound (s) -3- (4 - ((4-morpholinomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidin-2,6-dione, an amount of 90 to 99, 9 percent by weight of the total weight of a mixture of starch and lactose as carrier or excipient, and stearic acid as a lubricant; its use in the treatment of cancer and autoimmune diseases, among others. | |
| CL2023003691A1 (en) | Urea derivatives that can be used to treat cancer | |
| UY39608A (en) | COMPOUNDS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH STING ACTIVITY | |
| CL2024000327A1 (en) | Compounds that inhibit the alpha isoform of pi3k and methods for treating cancer | |
| UY30880A1 (en) | 7-ALCOXYCINOLIN-3-REPLACED CARBOXAMIDS AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PREPARATION PROCEDURES AND APPLICATIONS | |
| AR123760A1 (en) | METHODS TO TREAT CANCER | |
| AR123576A1 (en) | METHODS TO TREAT CANCER | |
| WO2022072645A3 (en) | Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer |